KOCAA
KYMR icon

Knights of Columbus Asset Advisors’s Kymera Therapeutics KYMR Stock Holding History

Knights of Columbus Asset Advisors’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.1M Buy
18,313
+2,441
+15% +$210K 0.11% 204
2026
Q1 		$1.32M Buy
15,872
+2,982
+23% +$236K 0.07% 238
2025
Q4 		$1M Sell
12,890
-6,001
-32% -$405K 0.06% 262
2025
Q3 		$1.07M Buy
+18,891
New +$852K 0.06% 258

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Knights of Columbus Asset Advisors's KYMR Position: Q2 2026 in Review

Knights of Columbus Asset Advisors increased its Kymera Therapeutics (KYMR) stake by 15% in Q2 2026, buying an estimated $210K and bringing the position to 18,313 shares worth $2.1M. The position accounts for 0.11% of the portfolio, ranked #204.

Knights of Columbus Asset Advisors first reported a position in KYMR in Q3 2025 and has held it in 4 quarters since. 275 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Knights of Columbus Asset Advisors held 18,313 shares of Kymera Therapeutics worth $2.1M as of Q2 2026.
  • Knights of Columbus Asset Advisors bought 2,441 Kymera Therapeutics shares in Q2 2026, an estimated $210K.
  • Kymera Therapeutics made up 0.11% of Knights of Columbus Asset Advisors's portfolio in Q2 2026, its #204 holding.
  • Knights of Columbus Asset Advisors first reported a position in Kymera Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 275 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Knights of Columbus Asset Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.